PUBLISHER: The Business Research Company | PRODUCT CODE: 1945319
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945319
Hospital-acquired infection testing kits are utilized to examine infections contracted by individuals within a healthcare facility. These kits play a crucial role in identifying infections associated with pathogens such as vancomycin-resistant enterococci (VRE), methicillin-resistant Staphylococcus aureus (MRSA), multi-resistant gram-negative bacilli, norovirus, and Clostridium difficile.
The primary components of hospital-acquired infection testing kits include instruments, reagents, and consumables. Instruments for these testing kits encompass various tools essential for hospital-acquired infections testing, aiding scientists in cultivating new cells in culture media for purposes such as drug development, tissue culture, engineering, gene therapy, vaccine production, and toxicity testing. Hospital-acquired infections testing kits address pathogens such as viruses, bacteria, and fungi through sterilization, chemical treatments, and radiation methods. The testing extends to identifying infections such as pneumonia, urinary tract infection, bloodstream infection, surgical site infection, MRSA infection, and others. These kits find applications in drug-resistance testing and disease testing.
Tariffs are impacting the hospital acquired infections testing kits market by increasing costs of imported reagents, molecular assay kits, diagnostic instruments, and electronic components. Healthcare facilities in North America and Europe are most affected due to dependence on imported testing supplies, while Asia-Pacific faces export-related pricing pressures. These tariffs are increasing testing costs and procurement challenges for hospitals. However, they are also encouraging local manufacturing of consumables, regional reagent production, and strengthened domestic diagnostic supply chains.
The hospital acquired infections testing kits market research report is one of a series of new reports from The Business Research Company that provides hospital acquired infections testing kits market statistics, including hospital acquired infections testing kits industry global market size, regional shares, competitors with a hospital acquired infections testing kits market share, detailed hospital acquired infections testing kits market segments, market trends and opportunities, and any further data you may need to thrive in the hospital acquired infections testing kits industry. This hospital acquired infections testing kits market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The hospital acquired infections testing kits market size has grown strongly in recent years. It will grow from $4.79 billion in 2025 to $5.19 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to increasing hospital infection surveillance, rising prevalence of antibiotic-resistant pathogens, expansion of clinical microbiology labs, implementation of infection control protocols, availability of molecular diagnostic tools.
The hospital acquired infections testing kits market size is expected to see strong growth in the next few years. It will grow to $7.2 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increasing focus on early infection detection, rising investments in hospital safety infrastructure, expansion of rapid testing adoption, growing demand for automated diagnostic workflows, advancements in molecular diagnostics technology. Major trends in the forecast period include increasing adoption of rapid diagnostic test kits, rising use of molecular testing for hais, growing integration of automated diagnostic instruments, expansion of point-of-care infection testing, enhanced focus on multi-pathogen detection.
The increasing number of healthcare settings is anticipated to drive the growth of the hospital-acquired infections testing kits market in the coming years. A healthcare setting encompasses a range of facilities and services, including acute care hospitals, urgent care centers, rehabilitation facilities, nursing homes, and long-term care facilities, collectively delivering comprehensive healthcare solutions. Hospital-acquired infections testing kits serve as essential tools for identifying and preventing nosocomial infections, thereby improving patient safety across healthcare facilities. For example, in May 2023, according to the American Hospital Association, a US-based healthcare industry trade group, the total number of hospitals in the U.S. region increased significantly from 6,093 in 2022 to 60,129 in 2023. In addition, admissions in community hospitals also rose, increasing from 31,393,318 in 2022 to 31,967,073 in 2023. Consequently, the growing number of healthcare settings is fueling the hospital-acquired infections testing kits market.
The rising number of surgical procedures is expected to drive growth in the hospital-acquired infections testing kits market. Surgical procedures are medical operations performed in operating theaters that involve incision, excision, or tissue manipulation, typically requiring regional or general anesthesia or profound sedation to manage pain. The increase in surgical procedures is largely driven by an aging population, as older adults require more medical interventions for age-related conditions and chronic diseases. Higher surgical volumes increase demand for testing kits, as surgeries create entry points for pathogens, raising the risk of infections that require systematic detection and monitoring through specialized diagnostic tools. For example, in May 2025, the Australian Institute of Health and Welfare, an Australia-based government agency providing health and welfare statistics, reported that hospitalizations involving surgery rose from 3.0 million in 2022-23 to 3.1 million in 2023-24, an increase of 100,000 cases. This rise in surgical procedures is therefore driving growth in the hospital-acquired infections testing kits market.
Major companies in the hospital-acquired infections (HAI) testing kits market are focusing on developing advanced point-of-care antimicrobial susceptibility testing (AST) solutions to enable rapid diagnosis, guide targeted therapy, and address antimicrobial resistance (AMR). Point-of-care AST uses proprietary microfluidic technology to quickly detect bacterial presence and assess antibiotic effectiveness directly from patient urine samples, reducing diagnostic delays and improving treatment decisions. For example, in June 2023, Sysmex Corporation, a Japan-based diagnostics company, launched the world's first point-of-care testing system in Europe capable of performing antimicrobial susceptibility testing in just 30 minutes. Using a microfluidic-based AST approach for patients suspected of urinary tract infections, the system significantly shortens turnaround time and supports antimicrobial stewardship in primary care by enabling timely and informed antibiotic use, contributing to global efforts to combat AMR.
Major companies operating in the hospital acquired infections testing kits market are Becton Dickinson and Company, Abbott Laboratories, Cepheid, F. Hoffmann-La Roche Ltd, STERIS plc, QIAGEN, Meridian Bioscience Inc., BioMerieux SA, GE Healthcare, Seegene, SD Biosensor, Fujirebio, Sysmex Corporation, Getein Biotech, Hangzhou Biotest Biotech, AmonMed Biotechnology, Beijing Tigsun Diagnostics, Hunan Lituo Biotechnology, ImmunoScience, Vivacheck Lab
North America was the largest region in the hospital-acquired infections testing kits market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hospital acquired infections testing kits market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the hospital acquired infections testing kits market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The hospital-acquired infections testing kits market consist of sales of testing kits and devices. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Hospital Acquired Infections Testing Kits Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses hospital acquired infections testing kits market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for hospital acquired infections testing kits ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hospital acquired infections testing kits market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.